Skip to content

US · MSLE · BIOTECHNOLOGY

Satellos Bioscience Inc. (MSLE) intrinsic value and stock valuation

$5.68as of 2026-11-21 · Mkt cap 12.92M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Satellos Bioscience Inc. DCF and intrinsic value

InvestorsCraft values MSLE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MSLE’s statements →

Satellos Bioscience Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Toronto, ON M5J 2J1 satellos.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-24.87M
20112025
Free cash flow
-$-23.6M
20102025
Total equity
$27.8M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-26.46M-$-19.38M-$-11.66M-$-8.34M-$-4.89M
Net income-$-24.87M-$-19.58M-$-11.98M-$-11.21M-$-12.16M
EPSd-$-20.39M-$-2.05M-$-1.66M-$-3.77M-$-6.05M
Operating cash flow-$-23.6M-$-17.4M-$-14.42M-$-5.73M-$-3.95M
Capital expenditure-$-10K-$0.00-$-20K-$0.00-$-10K
Free cash flow-$-23.6M-$-17.41M-$-14.44M-$-5.73M-$-3.95M
Total assets$31.9M$50.9M$33.4M$6.14M$9.87M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-9.8M-$-40.18M-$-16.63M-$-1.9M-$-3.82M
Total equity$27.8M$47.3M$30.7M$3.34M$8.22M
Cash and short-term investments$27.7M$48.7M$29.8M$1.9M$3.82M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$10K$20K$10K$330K$170K
Gross profit-$-10K-$-20K-$-10K-$-330K-$-170K
Research and development expenses$18.4M$13.7M$6.65M$3.7M$1.9M
Selling, general and administrative expenses$7.44M$5.16M$4.57M$3.92M$1.13M
Other expenses$590K$550K$440K$390K$1.69M
Operating expenses$26.5M$19.4M$11.7M$8M$4.72M
Cost and expenses$26.5M$19.4M$11.7M$8.34M$4.89M
Interest income$1.36M$960K$1M$60K$10K
Interest expense$0.00$0.00$130K$0.00$770K
Depreciation and amortization$10K$10K$10K$330K$130K
Ebitda-$-26.45M-$-19.56M-$-11.84M-$-10.87M-$-11.26M
Operating income-$-26.46M-$-19.38M-$-11.66M-$-8.34M-$-4.89M
Total other income/expenses, net$1.76M-$-200K-$-320K-$-2.13M-$-10.78M
Income before tax-$-24.7M-$-19.58M-$-11.98M-$-8.34M-$-15.67M
Income tax expense$170K$0.00$0.00$0.00-$-40K
Net income-$-24.87M-$-19.58M-$-11.98M-$-11.21M-$-12.16M
Weighted average shares outstanding$1.22M$9.56M$7.2M$2.97M$2.01M
Weighted average diluted shares outstanding$1.22M$9.56M$7.2M$2.97M$2.01M
Balance sheet
20252024202320222021
Cash and short-term investments$27.7M$48.7M$29.8M$1.9M$3.82M
Net receivables$370K$440K$440K$260K$410K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$31.9M$50.9M$30.4M$2.21M$4.27M
Property, plant and equipment, net$10K$0.00$10K$10K$10K
Goodwill and intangible assets$0.00$0.00$3.92M$3.88M$5.6M
Long-term investments$0.00$0.00$30K$40K$0.00
Total non-current assets$10K$0.00$3M$3.93M$5.6M
Total assets$31.9M$50.9M$33.4M$6.14M$9.87M
Accounts payable$1.77M$2.07M$780K$1.45M$890K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.11M$3.59M$2.73M$2.8M$1.65M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$4.11M$3.59M$2.73M$2.8M$1.65M
Common stock$85.8M$73.7M$62.7M$29.9M$22.4M
Retained earnings-$-81.97M-$-52.68M-$-48.33M-$-31.3M-$-16.04M
Accumulated other comprehensive income (loss)-$-1.72M-$-150K$480K-$-10K-$0.00
Total equity$27.8M$47.3M$30.7M$3.34M$8.22M
Total investments$17.9M$8.5M$13.2M$40K$2.38M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-9.8M-$-40.18M-$-16.63M-$-1.9M-$-3.82M
Cash flow statement
20252024202320222021
Net income-$-24.87M-$-19.58M-$-15.89M-$-11.21M-$-12.16M
Depreciation and amortization$0.00$10K$10K$330K$130K
Stock-based compensation$3.23M$1.47M$1.64M$1.43M$760K
Change in working capital-$-1.48M-$-710K$280K$980K-$-380K
Accounts receivable$70K-$-30K-$-240K$260K-$-50K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-23.6M-$-17.4M-$-14.42M-$-5.73M-$-3.95M
Investments in property, plant and equipment-$-10K-$0.00-$-10K-$0.00-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$1.37M
Net cash used for investing activities-$-9.42M$4.42M-$-17.54M-$0.00$1.36M
Common stock issued$2.24M$29.8M$24.5M$2.75M$5.55M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.24M$37.3M$51M$2.75M$5.84M
Net change in cash-$-30.27M$24.8M$15.2M-$-1.17M$3.26M
Cash at end of period$9.8M$40.2M$16.6M$1.9M$3.82M
Operating cash flow-$-23.6M-$-17.4M-$-14.42M-$-5.73M-$-3.95M
Capital expenditure-$-10K-$0.00-$-20K-$0.00-$-10K
Free cash flow-$-23.6M-$-17.41M-$-14.44M-$-5.73M-$-3.95M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Satellos Bioscience Inc.

        Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

        CEO
        Frank Gleeson
        Employees
        18
        Beta
        1.17

        Explore

        Frequently asked questions

        What is the intrinsic value of Satellos Bioscience Inc. (MSLE)?

        InvestorsCraft does not currently publish an intrinsic value for MSLE. How the IC value is calculated.

        Is MSLE undervalued?

        InvestorsCraft does not publish an undervaluation signal for MSLE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.